{{Drugbox
| drug_name = 
| IUPAC_name        = (4-Benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone
| image             = NSI-189 structure.svg
| width = 200
| alt               =
| caption           =

<!-- Clinical data -->
| tradename         =
| Drugs.com         =
| MedlinePlus       =
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      = N
| pregnancy_category=
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = 未管制
| routes_of_administration = [[口服给药|Oral]]<ref name="FavaJohe2015" />

<!-- Pharmacokinetic data -->
| bioavailability   =
| protein_bound     =
| metabolism        =
| elimination_half-life = 17.4–20.5 hours<ref name="FavaJohe2015" />
| excretion         =

<!-- Identifiers -->
|  CAS_number_Ref = {{cascite|changed|??}}
| CAS_number        = 1270138-40-3
| CAS_supplemental  = 
| ATCvet            =
| ATC_prefix        = 
| ATC_suffix        =
| PubChem           = 50922681
| DrugBank          =
| StdInChI = 1S/C22H30N4O/c1-18(2)10-12-24-21-20(9-6-11-23-21)22(27)26-15-13-25(14-16-26)17-19-7-4-3-5-8-19/h3-9,11,18H,10,12-17H2,1-2H3,(H,23,24)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = DYTOQURYRYYNOR-UHFFFAOYSA-N
|  ChemSpiderID = 32701740
<!-- Chemical data -->
| C=22 | H=30 | N=4 | O=1
| molecular_weight  = 366.4998 g/mol
| smiles = CC(C)CCNC1=C(C=CC=N1)C(=O)N2CCN(CC2)CC3=CC=CC=C3
}}
{{medical}}
'''NSI-189'''是一個{{tsl|en|experimental drug|實驗性藥物}},由{{tsl|en|Neuralstem, Inc.||Neuralstem, Inc.}}開發的[[抗抑鬱藥|抗抑鬱藥]]。用於治療[[重性抑郁障碍|重性抑郁障碍]] (MDD), [[認知障礙|認知障礙]]以及[[神经退行性疾病|神经退行性疾病]].<ref name="Bouhassira2015">{{cite book|author=Eric E. Bouhassira|title=The SAGE Encyclopedia of Stem Cell Research|url=http://books.google.com/books?id=LoiECgAAQBAJ&pg=PA843|date=15 June 2015|publisher=SAGE Publications|isbn=978-1-4833-4767-7|pages=843–|access-date=2016-05-05|archive-date=2017-02-15|archive-url=https://web.archive.org/web/20170215161004/https://books.google.com/books?id=LoiECgAAQBAJ&pg=PA843|dead-url=no}}</ref><ref name="FavaJohe2015">{{cite journal|last1=Fava|first1=M|last2=Johe|first2=K|last3=Ereshefsky|first3=L|last4=Gertsik|first4=L G|last5=English|first5=B A|last6=Bilello|first6=J A|last7=Thurmond|first7=L M|last8=Johnstone|first8=J|last9=Dickerson|first9=B C|last10=Makris|first10=N|last11=Hoeppner|first11=B B|last12=Flynn|first12=M|last13=Mischoulon|first13=D|last14=Kinrys|first14=G|last15=Freeman|first15=M P|title=A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients|journal=Molecular Psychiatry|year=2015|issn=1359-4184|doi=10.1038/mp.2015.178}}</ref><ref name="Neuralstem2016">{{Citation | author = Neuralstem | date = March 2016 | title = Neuralstem Inc. March 2016 Corporate Presentation | url = http://investor.neuralstem.com/download/March+2016+Corporate+Presentation%2B.pdf | accessdate = 25 March 2016 }}{{dead link|date=2018年2月 |bot=InternetArchiveBot |fix-attempted=yes }}</ref> 相關研究由美國[[國防高等研究計劃署|國防高等研究計劃署]] (DARPA)以及[[國立衛生研究院_(美國)|國立衛生研究院]] (NIH)出資。<ref name="Neuralstem2013">{{Cite web |url=http://investor.neuralstem.com/2013-04-22-FDA-Approves-Neuralstem-To-Treat-Final-Cohort-In-NSI-189-Phase-Ib-Trial-In-Major-Depressive-Disorder |title=FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In Major Depressive Disorder |accessdate=2016-05-05 |archive-date=2016-03-04 |archive-url=https://web.archive.org/web/20160304043501/http://investor.neuralstem.com/2013-04-22-FDA-Approves-Neuralstem-To-Treat-Final-Cohort-In-NSI-189-Phase-Ib-Trial-In-Major-Depressive-Disorder |dead-url=yes }}</ref> NSI-189的[[作用機轉|作用機轉]]為在[[海馬迴|海馬迴]]增強的[[神经发生|神經元新生]]以及其體積的增大，<ref name="Bouhassira2015" />但NSI-189達成此效果的機轉尚不明朗。{{tsl|en|ligand binding assay|配體結合研究}}目前為止無法找出其{{tsl|en|biological target||標靶}}<ref name="Neuralstem2016" />。 

此藥物由對10,269種化合物進行{{tsl|en|high-throughput screening||高通量篩檢}}而發現，其過程為尋找''in vitro''環境下有神經新生特性的化合物。<ref name="Neuralstem2016" />

==參見==
* {{tsl|en|4-Chlorokynurenine||4-Chlorokynurenine}} (AV-101)
* {{tsl|en|Buprenorphine/samidorphan||Buprenorphine/samidorphan}} (ALKS-5461)
* {{tsl|en|CERC-301||CERC-301}}
* {{tsl|en|CERC-501||CERC-501}} (LY-2456302)
* {{tsl|en|Dextromethorphan/quinidine||Dextromethorphan/quinidine}} (AVP-786/AVP-923)
* {{tsl|en|Esketamine||Esketamine}}
* [[氯胺酮|Ketamine]]
* {{tsl|en|NRX-1074||NRX-1074}}
* {{tsl|en|Rapastinel||Rapastinel}} (GLYX-13)

==參考資料==
{{Reflist|2}}

{{Antidepressants}}

[[Category:抗抑郁药物|Category:抗抑郁药物]]
[[Category:作用機轉不明的藥物|Category:作用機轉不明的藥物]]
[[Category:煙酰胺|Category:煙酰胺]]
[[Category:促智药|Category:促智药]]
[[Category:哌嗪|Category:哌嗪]]
[[Category:吡啶|Category:吡啶]]